These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12191617)

  • 1. Irreversible inhibitors of the erbB family of protein tyrosine kinases.
    Denny WA
    Pharmacol Ther; 2002; 93(2-3):253-61. PubMed ID: 12191617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.
    Denny WA
    Farmaco; 2001; 56(1-2):51-6. PubMed ID: 11347967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.
    Denny WA; Rewcastle GW; Bridges AJ; Fry DW; Kraker AJ
    Clin Exp Pharmacol Physiol; 1996 May; 23(5):424-7. PubMed ID: 8713682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.
    Bridges AJ
    Curr Med Chem; 1999 Sep; 6(9):825-43. PubMed ID: 10495354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
    Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
    Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
    Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
    J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
    Lackey KE
    Curr Top Med Chem; 2006; 6(5):435-60. PubMed ID: 16719802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
    Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
    J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
    Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
    J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
    Rewcastle GW; Denny WA; Bridges AJ; Zhou H; Cody DR; McMichael A; Fry DW
    J Med Chem; 1995 Sep; 38(18):3482-7. PubMed ID: 7658435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis.
    Singh P; Kumar R
    J Enzyme Inhib; 1998 Apr; 13(2):125-34. PubMed ID: 9629532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
    Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
    J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.